Whalesbook
ICICI Securities has reiterated its BUY recommendation for OneSource Specialty Pharma, setting a target price of INR 2,475. The brokerage notes a potential one-quarter delay in generic semaglutide launches due to Canadian regulatory hurdles. However, management remains optimistic, citing securing approvals in India, Brazil, and Saudi Arabia, and maintains its FY28 revenue guidance for the base business. With over 20 customers pre-booking GLP-1 capacity, the company targets USD 500 million in revenue and a ~40% EBITDA margin by FY28. Analyst projections show strong CAGR growth and margin expansion, though FY26/27E EPS estimates were adjusted downwards to account for the launch timeline shift.